OpGen, Inc.

OpGen, Inc. OpGen, Inc. (NASDAQ: OPGN) is harnessing the power of informatics and genomic analysis to provide complete solutions for infection prevention and treatment

OpGen is uniquely positioned to address the rising antibiotic resistance crisis and is harnessing the power of informatics and genomic analysis to provide complete solutions to protect patients in hospitals and healthcare networks. Using our large and ever-growing Acuitas Lighthouse® Knowledgebase of pathogens from around the world, we are developing disruptive technologies aimed to shift the para

digm for managing infectious diseases. Today, through our CLIA-certified clinical laboratory services, we provide rapid detection and analysis of antibiotic resistance and high resolution microbial sequence analysis. Our FDA-cleared, IVD products rapidly identify pathogens in positive blood cultures.

What is the Global Antibiotic Research & Development Partnership doing to combat  , which was last year identified as on...
08/14/2023

What is the Global Antibiotic Research & Development Partnership doing to combat , which was last year identified as one of the world’s leading causes of death. Learn more here: https://gardp.org/annual-report-2022/

08/11/2023

The Candida auris multi-drug-resistant and pan-resistant fungus poses a global health threat for three main reasons. It is often resistant to anti-fungal drugs, is difficult to identify and can spread in hospitals and nursing homes. Find out more in Episode 10 of the Superbugs and You podcast: https://ow.ly/IRwI50PoSNZ

Infections caused by highly drug resistant bacteria or ​“superbugs” are becoming more and more common, making antimicrobial resistance one of the world’s greatest health threats.

The World Health Organization has published the first global research agenda to address urgent health priorities to coun...
08/09/2023

The World Health Organization has published the first global research agenda to address urgent health priorities to counter : https://ow.ly/alGW50PoSui

Policy brief

The development of antimicrobials to address   has been hindered by a flawed marketplace which has resulted in a steady ...
08/08/2023

The development of antimicrobials to address has been hindered by a flawed marketplace which has resulted in a steady decline in the number of phase-III antibiotic candidates over the past 9 years.
The number of first-time drug approvals from 2020 to 2022 was ‘disappointingly low’ but there is still hope. Read this new study:

The need for new antibacterial drugs to treat the increasing global prevalence of drug-resistant bacterial infections has clearly attracted global attention, with a range of existing and upcoming funding, policy, and legislative initiatives designed to revive antibacterial R&D. It is essential t...

A new study has been launched to find out more about how   is best tackled in healthy people. Up to 2,000 people across ...
08/04/2023

A new study has been launched to find out more about how is best tackled in healthy people.
Up to 2,000 people across different UK populations are to be invited to submit stool samples and nose and throat swabs for the study, which will help scientists understand more about the factors influencing bacteria in our body.
By understanding more about the drivers of in the community, scientists hope to be better able to design ways to reduce antimicrobial-resistant infections.
Read here for more details:

The study aims to learn about antimicrobial resistance in healthy people to inform better ways of tackling antimicrobial resistant infections in different populations.

08/03/2023

Signed contract amendment is part of an overall strategic priority collaboration in the fight against AMR using Unyvero A30 platform in LMICs Next phase to cover full AMR assay and cartridge development, analytical testing and software development Related payments of up to approximately $0.6

OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration AgreementRead the full release here:
08/03/2023

OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement

Read the full release here:

Signed contract amendment is part of an overall strategic priority collaboration in the fight against AMR using Unyvero A30 platform in LMICs Next phase to cover full AMR assay and cartridge development, analytical testing and software development Related payments of up to approximately $0.6

08/03/2023

Join us to hear about ‘Multiplex Molecular Panel as a Supplement to Routine Culture for Tissue Infection’ poster by C. R. Cox et al at the 33rd Annual Open Scientific Meeting of the Musculoskeletal Infection Society in Salt Lake City, Utah from August 4-5 (Monitor 5, 23-AEP-1087):

PROGRAM General information 33rd Annual Open Scientific Meeting Musculoskeletal Infection Society Aug 4-5, 2023 Salt Lake City, Utah United States In Person and Virtual meeting with podium, poster and symposia presentations Registration Starts from: 28-Feb-2023 to 30-Jul-2023 LOGIN TO MEETING Meetin...

A new network is being set up to help tackle the main drivers of  . The Centres for Antimicrobial Optimisation Network (...
08/02/2023

A new network is being set up to help tackle the main drivers of . The Centres for Antimicrobial Optimisation Network (CAMO-Net), funded by Wellcome, will be based at Imperial College London and University of Liverpool.
The aim is to address the global impact of AMR on human health by fostering research partnerships across low, middle and high resource settings and across urban and rural environments.
More details here:

The new network called CAMO-Net will support translational research to help tackle the main drivers of antimicrobial resistance.

Global estimates of hospital-acquired  -resistant infections now top 136 million a year. China, Pakistan and India are n...
07/31/2023

Global estimates of hospital-acquired -resistant infections now top 136 million a year. China, Pakistan and India are new hot-spots but, among high income countries, the USA is faring worst. More details in this new blockbuster report: https://ow.ly/oBSJ50P1ys0

Ruchita Balasubramanian and colleagues, estimate the incidence of hospital-associated infections resistant to antibiotics in 195 countries using point prevalence survey data from across the globe.

Effectively combatting   requires a paradigm shift from the pharmaceuticals industry - but right now the kind of small b...
07/28/2023

Effectively combatting requires a paradigm shift from the pharmaceuticals industry - but right now the kind of small biotech firms responsible for developing most new antibiotics continue to face bankruptcy. That was the frightening conclusion of a recent webinar. Watch it here🎥:

Congressional policymakers, federal policymakers, their advisors, and stakeholders interested in addressing drug-resistant infections and antimicrobial resis...

  will be a worse pandemic than  . That’s the frightening forecasts from former US Secretary of Health Donna Shalala and...
07/27/2023

will be a worse pandemic than . That’s the frightening forecasts from former US Secretary of Health Donna Shalala and two top US scientists. Read here for more information:

By 2050, it’s projected that as many as 10 million people worldwide could die as a result of antimicrobial resistance each year.

The ‘silent pandemic’ of   will kill more than five million across Australia, Japan, Singapore and 34 other western Paci...
07/25/2023

The ‘silent pandemic’ of will kill more than five million across Australia, Japan, Singapore and 34 other western Pacific countries this decade, posing a ‘serious threat to health systems and economies,’ according to a new report. The World Health Organization prediction would make a bigger killer than HIV/Aids and tuberculosis. Full details here:

Drug-resistant infections will become a bigger killer in the region than HIV/Aids and tuberculosis, according to the WHO

New data has demonstrated the existence of severe   among non-typhoidal Salmonella isolated from food in China. More det...
07/21/2023

New data has demonstrated the existence of severe among non-typhoidal Salmonella isolated from food in China. More details here:

Announcing a new article publication for Zoonoses journal. Non-typhoidal Salmonella (NTS) is a major cause of human salmonellosis globally. Food animals are major NTS reservoirs.

The shocking story of the leg infection that struck down gymnast Tori Kinamon is a reminder of why   is a 'bigger threat...
07/20/2023

The shocking story of the leg infection that struck down gymnast Tori Kinamon is a reminder of why is a 'bigger threat to global health' than AIDS or Ebola. 🎥Watch this alarming trailer for ‘Race Against Resistance: The Life and Death Struggle to Save Antibiotics’.
🎥https://ow.ly/EZ1X50Pe2i0

feature presented by AMR Action Fund, Shionogi, Pfizer and Merck.When college gymnast Tori Kinamon was struck down with an infection in her leg, an illne...

For true stories from scientists and patients and scientists on the frontline in the battle against   all over the world...
07/18/2023

For true stories from scientists and patients and scientists on the frontline in the battle against all over the world, listen to the ‘Superbugs and You’ podcasts from the Antimicrobial Resistance Fighters Coalition. Tune in here to the latest episode on 𝘈𝘤𝘪𝘯𝘦𝘵𝘰𝘣𝘢𝘤𝘵𝘦𝘳 𝘣𝘢𝘶𝘮𝘢𝘯𝘯𝘪𝘪, a type of bacteria that has become a major concern in public health, particularly in healthcare facilities, due to its increasing antibiotic resistance 👉: https://ow.ly/3QYZ50P1vpG

Five reasons why we can’t give up the fight against  . It infects 800,000 people a year, killed 100 people a day in 2020...
07/17/2023

Five reasons why we can’t give up the fight against . It infects 800,000 people a year, killed 100 people a day in 2020, lives everywhere in animals, food, plants and the environment and entails substantial health costs. Oh, and it damages the economy. More details:
https://ow.ly/l3kg50P1uPf

Address

Gaithersburg, MD

Alerts

Be the first to know and let us send you an email when OpGen, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share